References
- Abusnina A, Lugnier C. 2017. Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families. Cell Signal. 39:55–65.
- Arya H, Syed SB, Singh SS, Ampasala DR, Coumar MS. 2018. In silico investigations of chemical constituents of Clerodendrum colebrookianum in the anti-hypertensive drug targets: ROCK, ACE, and PDE5. Interdiscip Sci. 10(4):792–804.
- Bischoff E. 2004. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 16 Suppl 1:S11–S14.
- Chen CY. 2009. Computational screening and design of traditional Chinese medicine (TCM) to block phosphodiesterase-5. J Mol Graph Model. 28(3):261–269.
- Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. 1998. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338(20):1397–1404.
- Goldstein I. 2000. Male sexual circuitry. working group for the study of central mechanisms in erectile dysfunction. Sci Am. 283(2):70–75.
- Huang N, Shoichet BK, Irwin JJ. 2006. Benchmarking sets for molecular docking. J Med Chem. 49(23):6789–6801.
- Loza-Mejía MA, Salazar JR, Sánchez-Tejeda JF. 2018. In silico studies on compounds derived from calceolaria: phenylethanoid glycosides as potential multitarget inhibitors for the development of pesticides. Biomolecules. 8(4):121.
- Matsson P, Kihlberg J. 2017. How big is too big for cell permeability? J Med Chem. 60(5):1662–1664.
- Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. 2012. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem. 55(14):6582–6594.
- Petit J, Meurice N, Kaiser C, Maggiora G. 2012. Softening the Rule of Five-where to draw the line? Bioorg Med Chem. 20(18):5343–5351.
- Oboh G, Adebayo AA, Ademosun AO, Boligon AA. 2017. In vitro inhibition of phosphodiesterase-5 and arginase activities from rat penile tissue by two Nigerian herbs (Hunteria umbellata and Anogeissus leiocarpus). J Basic Clin Physiol Pharmacol. 28(4):393–401.
- Ojewole JA, Drewes SE, Khan F. 2006. Vasodilatory and hypoglycaemic effects of two pyrano-isoflavone extractives from Eriosema kraussianum N. E. Br. [Fabaceae] rootstock in experimental rat models. Phytochemistry. 67(6):610–617.
- Pavan V, Mucignat-Caretta C, Redaelli M, Ribaudo G, Zagotto G. 2015. The old made new: natural compounds against erectile dysfunction. Arch Pharm (Weinheim). 348(9):607–614.
- Ribaudo G, Pagano MA, Pavan V, Redaelli M, Zorzan M, Pezzani R, Mucignat-Caretta C, Vendrame T, Bova S, Zagotto G. 2015. Semi-synthetic derivatives of natural isoflavones from Maclura pomifera as a novel class of PDE-5A inhibitors. Fitoterapia. 105:132–138.
- Ribaudo G, Pagano MA, Bova S, Zagotto G. 2016. New therapeutic applications of phosphodiesterase 5 inhibitors (PDE5-Is). Curr Med Chem. 23(12):1239–1249.
- Ribaudo G, Vendrame T, Bova S. 2017. Isoflavones from Maclura pomifera: structural elucidation and in silico evaluation of their interaction with PDE5. Nat Prod Res. 31(17):1988–1994.
- Ribaudo G, Zanforlin E, Canton M, Bova S, Zagotto G. 2018. Preliminary studies of berberine and its semi-synthetic derivatives as a promising class of multi-target anti-parkinson agents. Nat Prod Res. 32(12):1395–1401.
- Srivani P, Srinivas E, Raghu R, Sastry GN. 2007. Molecular modeling studies of pyridopurinone derivatives-potential phosphodiesterase 5 inhibitors. J Mol Graph Model. 26(1):378–390.
- Tömöri T, Hajdú I, Barna L, Lorincz Z, Cseh S, Dormán G. 2012. Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds' repositories: biological evaluation. Mol Divers. 16(1):59–72.
- West E, Krychman M. 2015. Natural aphrodisiacs-A review of selected sexual enhancers. Sex Med Rev. 3(4):279–288.
- Yafi FA, Sharlip ID, Becher EF. 2018. Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. Sex Med Rev. 6(2):242–252.